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Summary
Acute kidney injury (AKI) is the rapid deterioration of renal function, diagnosed on the basis 
of an increase in serum creatinine and abnormal urinary parameters. AKI is associated with 
increased risk of mortality or chronic kidney disease (CKD).
The aim of the study was to develop an experimental model for AKI resulting from Escheri-
chia coli-induced pyelonephritis. E. coli was isolated from a patient with clinical symptoms of 
urinary tract infection (UTI).
The study included three groups of female Wistar rats (groups 1, 2 and 3), in which pyeloneph-
ritis was induced by transurethral inoculation with highly virulent E. coli (105, 107 and 109 cfu/
ml, respectively). Urine and blood samples for analysis were obtained prior to the inoculation 
(day 0), as well as 7, 14 and 21 days thereafter.
Aside from a microbiological examination of urine samples, daily urine output, serum creati-
nine (CreaS), creatinine clearance (CrCl), interleukin 6 (IL-6), fractional excretion of sodium 
(FENa) and fractional excretion of urea (FEUrea) were determined. A histopathological exa-
mination of kidney and urinary bladder specimens was conducted as well. While UTI-related 
pyelonephritis developed irrespective of E. coli inoculum size, AKI was observed only following 
transurethral administration of E. coli at the intermediate and high dose, i.e. 107 and 109 cfu/
ml, respectively (group 2 and 3).
An increase in CreaS and abnormal diuresis were accompanied by changes in parameters 
specific for various forms of AKI, i.e. FENa and FEUrea. Based on these changes, administration 
of E. coli at 107 cfu/ml was demonstrated to induce renal AKI, whereas inoculation with 109 
cfu/ml seemed to cause not only ascending pyelonephritis, but perhaps also bacteremia and 
urosepsis (prerenal component of AKI).
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IntroductIon
Acute kidney injury (AKI) is a clinical syndrome char-
acterized by the rapid impairment of renal functions 
manifesting themselves as an increase in serum creati-
nine and urination disorders, classified on the basis of 
the Kidney Disease Improving Global Outcomes (KDIGO) 
criteria [36]. AKI may develop as a consequence of vari-
ous renal diseases, plausibly due to the impaired perfu-
sion of the kidneys induced by a decrease in circulating 
blood volume, toxic damage or urinary obstruction [27].
Renal causes of AKI include also tubulointerstitial dise-
ases, such as pyelonephritis. The latter is typically 
a consequence of a bacterial infection. The risk of pyelo-
nephritis-related AKI increases whenever the course of 
the underlying infection is complicated, mainly due to 
anatomic abnormalities of the urinary tract, long-term 
catheterization, immunosuppression, pregnancy or 
absence of one kidney [24,37]. According to literature, 
AKI may develop in ca. 2-3% of adults with complicated 
pyelonephritis [14].
An increase in creatinine levels and urinary disorders 
observed during the course of pyelonephritis-related 
AKI result from impaired renal perfusion. The latter is 
mediated by pro-inflammatory cytokines released by 
white blood cells accumulated at the site of the inflam-
mation. A decrease in glomerular filtration rate (GFR) 
causes alterations of the tubules, such as the destruction 
of actin cytoskeleton, epithelial intercellular relaxation, 
impaired function of integrins and epithelial exfoliation 
into the tubular lumen [28,34]. Clogging of tubules by 
uromodulin casts and exfoliated epithelial cells results 
in an increase in intratubular hydrostatic pressure. 
Renal ischemia is further enhanced due to a predomi-
nance of locally synthesized vasopressors, such as endo-
thelin and thromboxanes, over vasodilators, e.g. nitric 
oxide (NO) and prostacyclin [23]. Regeneration of renal 
tissue is a long-term process that may eventually lead to 
the total restoration of kidney function; nevertheless, in 
nearly a half of the cases, AKI results in permanent renal 
impairment [1,38,41].
In previous experimental studies, ascending AKI resul-
ting from pyelonephritis has been induced by intra-
bladder (laparotomic) [3,12] or transurethral [9,18] 
administration of an etiological factor (fungus, bacte-
rium), its direct delivery to renal parenchyma [2,7,40] or 
intravenous injection [35,39]. The transurethral model 
for pyelonephritis induction accurately mimics pathoge-
nesis of UTI in humans. Aside from anesthesia, the only 
invasive procedure is urinary catheterization, which 
minimizes the risk of complications. Minimal invasi-
veness of the procedure and the lack of organ damage 
result in relatively low morbidity.
The aims of the study were:
•  to develop an experimental model for ascending AKI 
being a consequence of pyelonephritis caused by infec-
tion with E. coli, the most common organism isolated 
from patients with bacterial UTI;
•  to analyze the relationship between the inoculum of 
E.coli used to induce pyelonephritis, the course of infec-
tion and the degree of kidney damage.
MaterIals and Methods
Animals. 
The study included 30 female Wistar rats 10 weeks of age 
and ca. 200 g body weight. The animals were kept under 
a 12 h day-to-night cycle with unlimited access to water 
and food (Labofeed, Kcynia, Poland). All experimental 
procedures were approved by the Ethics Committee for 
Experiments on Animals at the Jagiellonian University 
in Cracow (decision no. 133/2012). 
Experimental groups. 
The rats were divided into three groups, 10 animals each. 
Depending on a group, pyelonephritis was induced by 
transurethral inoculation with 500 µl of suspension con-
taining 105 (group 1), 107 (group 2) or 109 cfu/ml (group 
3) of E. coli. The procedure was conducted under gen-
eral anesthesia (pentobarbital, Morbital, Biowet Puławy, 
Poland, 20 mg/kg intraperitoneally).
Urine and blood parameters determined prior to inocu-
lation with the bacteria (day 0) constituted the reference 
value for further measurements. Since no significant 
intergroup differences were found at day 0, the results 
were pooled and the mean values for all 30 animals were 
considered as the baseline. This enabled us to apply the 
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3R principle and to reduce the number of examined 
animals due to a more accurate selection of statistical 
methods [31].
Bacteria. 
E. coli used in the experiment originated from a patient 
with acute pyelonephritis. The strain expressed genes 
for several virulence factors, such as FimH, papC and 
sfaD/E for type 1 adhesin, type P and S fimbriae, respec-
tively. Furthermore, the isolate tested positively for iroN 
gene encoding a receptor for iron ions, salmochelin, as 
well as for cnf-1 gene encoding cytotoxins, among them 
tumor necrosis factor type 1 (TNF1).
Sampling and analysis of the material. 
Prior to the induction of bacterial pyelonephritis (day 
0), as well as 7, 14 and 21 days thereafter, blood samples 
for biochemical analyses were obtained from the tail 
vein, and urine samples were collected for microbiologi-
cal examination, determination of biochemical param-
eters (creatinine, sodium, urea, IL-6) and measurement 
of 24-h urine output (metabolic cage for rats, 150 - 300g, 
Tecniplast, Italy).
Furthermore, 24-h ingestion of water was determined at 
days 0, 7, 14 and 21, along with body temperature the 
studied rats (digital rectal thermometer for rodents, 
Vivari, UK).
During the course of microbiological examination, urine, 
in 1-μl aliquots, was cultured onto appropriate differen-
tiating media: Columbia Lab-Agar Base (Biocorp) with 
5% sheep blood for the isolation of microorganisms with 
different growth requirements (aerobic Gram-positive 
and Gram-negative bacteria), and Mac Conkey Lab-Agar 
(Biocorp) for the isolation of Enterobacteriaceae (Gram-
negative bacilli). The dishes were incubated for 24 h 
at 37°C under aerobic conditions. Then, growing colo-
nies were identified and counted; bacterial counts were 
expressed as cfu per 1 ml of urine.
Concentrations of sodium in blood and urine were deter-
mined with the aid of a flame photometer (Corning 450). 
Blood and urinary concentrations of creatinine were 
measured with Cobas 6000 analyzer, using C501 bio-
chemical module (Roche). Urinary IL-6 was determined 
by means of ELISA, with Rat IL-6 ELISA KIT (RayBiotech®, 
USA).
On the 21st day of the experiment, the animals were killed 
by a pentobarbital overdose (Morbital, Biowet Puławy, 
Poland, 100 mg/kg intraperitoneally). Then kidney and 
urinary bladder specimens for histopathological exami-
nation were obtained, washed in saline, and fixed for 24 h 
in 8% formalin solution in phosphate buffer (PBS, pH 7.4). 
Subsequently, the tissue was washed with running water 
for 2 h and dehydrated in ascending ethanol gradient 
(50-100%). Before being embedded in paraffin, the speci-
mens were treated with xylene, and then incubated for 
2 h at 37°C with xylene and paraffin mixture in 1:1 ratio. 
Subsequently, the material was treated twice with pure 
paraffin (2 h at 62ºC), embedded in paraffin blocks, cut 
with a microtome, mounted onto glass slides and dried 
in an incubator at 37°C. The severity of inflammation was 
assessed in 10 consecutive fields of hematoxylin-eosin 
(HE)-stained slides, using an AXIOPHOT light microscope 
(Zeiss, Germany). During the microscopic analysis, the 
location and characteristics of neutrophil and mononu-
clear cell infiltrate were determined within the kidney 
parenchyma and urinary bladder wall.
Statistical analysis. 
Statistical analysis was conducted with Statistica 8 
(StatSoft). The results for each group, presented in the 
form of tables and graphs, were expressed as a mean 
and standard deviation. Pooled results for all animals, 
determined prior to bacterial inoculation, were consid-
ered as the baseline for all analyses. Intergroup com-
parisons were conducted with Fisher’s ANOVA and HSD 
Tukey test. The differences were considered significant 
at p≤0.05.
results
Microbiological examination of urine
Following the induction of pyelonephritis, all animals, 
irrespective of the group and experiment stage, pre-
sented with bacteriuria. No association was found 
between the size of E. coli inoculum and the amount of 
bacteria recovered from urine, and the analyzed groups 
did not differ significantly in terms of their urinary bac-
terial counts (Table 1).
Table 1. The microbiological examination of urine (the result given in cfu/ml)
Day
Group 1
105cfu/ml
Group 2
107cfu/ml
Group 3
109cfu/ml
ANOVA
0 <101 <101 <101
7 2x106±5x106 4.8x104±7,1x104 13.5x104±14,5x104 NS
14 2x106±5x106 3.8x104±2,9x104 2.5x106±3,8x106 NS
21 9x104±1x105 5.3x104±1,5x104 3.5x106±8x106 NS
NS – not statistically significant
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Moreover, significant differences were found in 24 h urine 
output of animals from groups 1, 2 and 3 (Figure 1).
CreaS
An increase in CreaS, corresponding to the deterioration 
of renal function, was observed as early as at day 7. In 
group 3, CreaS was significantly higher than at the base-
line beginning at day 7, and in group 2 starting at day 14. 
Moreover, significant differences were observed in CreaS 
of animals from group 1 and 3 (Figure 2).
ClCr
Animals from group 3 presented with significantly lower 
CrCl values than at the baseline at days 7 and 14, and rats 
from group 2 no earlier than at day 14. Moreover, signi-
ficant differences were found in CrCl of rats from expe-
rimental groups 1, 2 and 3 (Table 2).
FENa
In animals from group 1, FENa determined at day 7 was 
significantly lower than at the baseline. A similar pheno-
menon was also documented in group 3, but the signifi-
cant decrease in FENa was observed not only at day 7, 
but also at day 21. In contrast, in animals from group 
2, FENa determined at the 14th day of the experiment 
was significantly higher than the baseline. Furthermore, 
Histopathological analysis of kidney specimens
Animals from group 1 presented with chronic pyelo-
nephritis and tubulointerstitial nephritis, manifesting 
as a presence of low-grade lymphocytic infiltration. 
Inflammation was limited to the renal medulla.
In specimens from group 2, chronic pyelonephritis 
was found, along with ulceration and tubulointerstitial 
nephritis with massive lymphocytic and granulocytic 
infiltration of both renal pelvis and medulla. Similar to 
group 1, however, the inflammation did not extend bey-
ond the medulla.
In rats from group 3, histopathologic examination reve-
aled chronic pyelonephritis and tubulointerstitial neph-
ritis involving both medulla and cortex of the kidneys, 
and characterized by massive lymphocytic and granulo-
cytic infiltration.
24 h urine collection
At 14 and 21 days after induction of pyelonephritis, all 
rats presented with lower 24 h urine output than at the 
baseline. While at day 14, 24 h urine output in all experi-
mental groups was significantly lower than at the base-
line. At day 21, urinary excretion in group 1 was similar 
to that observed prior to the bacterial inoculation, and 
the only significant differences referred to groups 2 and 3. 
 
Fig. 1. 24-hour urine collection (the result given in ml/24h)                    
# - statistically significant differences between the study group and the control group (p≤0,05)
* - statistically significant differences between the study group and the group 1 on the corresponding day (p ≤ 0.05)
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mals from group 3, i.e. those infected with the highest 
dose of E. coli. In group 2, the urinary concentration of 
IL-6 at day 14 was four times higher than those at the 
baseline. Furthermore, statistically significant differen-
ces were observed in the urinary concentrations of IL-6 
in rats from groups 1, 2 and 3 (Table 5).
24-h intake of water
No significant intergroup differences in 24-h intake of 
water were observed at days 7, 14 and 21. Irrespective of 
the group, mean intake of water amounted to 18-20.5 ml 
per animal per day.
statistically significant differences in FENa were found 
between experimental groups 1, 2 and 3 (Table 3).
FEUrea
At day 14, FEUrea in animals from group 3 was lower than 
in rats from groups 1 and 2, as well as lower, albeit insi-
gnificantly, from the respective baseline value (Table 4).
IL-6 in urine
The most pronounced, 40-fold increase in urinary IL-6 
was observed at the 14th day of the experiment in ani-
Fig. 2. CreaS (the result given in µmol/l)
# - statistically significant differences between the study group and the control group (p≤0.05)
* - statistically significant differences between the study group and the group 1 on the corresponding day (p ≤ 0.05)
 
Table 2. ClCr (the result given in ml/min)
Day
Group 1.
105cfu/ml
Group 2.
107cfu/ml
Group 3.
109cfu/ml
ANOVA
0 1.36±0.42 1.36±0.42 1.36±0.42
7
1.72±0.61 0.92±0.25
*p=0.003
0.77±0.22
#p=0.023 
*p=0.001
p<0.001
14
1.1±0.31 0.7±0.34
#p=0.001
0.66±0.19
#p=0,001
p<0.001
21 1.27±0.4 0.93±0.33 0.99±0.42 NS
NS – not statistically significant
# - statistically significant differences between the study group and the control group – HSD Tukey Test
* - statistically significant differences between the study group and the group 1 on the corresponding day – HSD Tukey Test
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Table 3. FENa (the result given in %)
Day
Group 1.
105cfu/ml
Group 2.
107cfu/ml
Group 3.
109cfu/ml
ANOVA
0 0.19±0.07 0.19±0..7 0,19±0.07
7
0.09±0.04
#p=0.002
0.18±0.07
*p=0.021
0.07±0.05
#p=0.001
**p=0,01
p<0.001
14 0.13±0.09
0.47±0.34
#p=0.002
*p=0.001
0.13±0.05
**p=0.003
p<0.001
21 0.1±0.05 0.19±0.17
0,09±0.04
#p=0.048
p=0.03
# - statistically significant differences between the study group and the control group – HSD Tukey Test
* - statistically significant differences between the study group and the group 1 on the corresponding day – HSD Tukey Test
** - statistically significant differences between the study group and the group 2 on the corresponding day – HSD Tukey Test
Table 4. FEUrea ( the result given in %)
Day
Group 1.
105cfu/ml
Group 2.
107cfu/ml
Group 3.
109cfu/ml
ANOVA
0 49.29±16.05 49.29±16.05 49.29±16.05
7 55.14±12.24 61.12±7.4 48±12.92 NS
14
65.57±11.94 63.12±17
40.17±3.97
*p=0.017
    **p=0.029
p=0.005
21 55.43±10.64 53.12±17.88 51.33±15.31 NS
NS – not statistically significant
* - statistically significant differences between the study group and the group 1 on the corresponding day – HSD Tukey Test
** - statistically significant differences between the study group and the group 2 on the corresponding day – HSD Tukey Test
Table 5. IL-6 in urine ( the result given in pg/24h)
Day
Group 1.
105cfu/ml
Group 2.
107cfu/ml
Group 3.
109cfu/ml
ANOVA
0 13.79±1.63 13.79±1.63 13.79±1.63
7 15.53±0.42 16.58±2.15
23.18±1.28
#p<0.001
* p<0.001
**p=0.001
p<0.001
14
21.85±6.51
55.7±1.31
#p<0.001
*p=0.001
554.25±19.25
#p<0.001
*p<0.001
**p<0.001
p<0.001
21 17.53±4.07 15±2.6
17.87±0.4
#p=0.048
p=0.046
# - statistically significant differences between the study group and the control group – HSD Tukey Test
* - statistically significant differences between the study group and the group 1 on the corresponding day – HSD Tukey Test
** - statistically significant differences between the study group and the group 2 on the corresponding day – HSD Tukey Test
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ups were at risk of AKI, and the latter was more evident 
in rats from group 3, i.e. those inoculated with 109 cfu/
ml of uropathogenic E. coli.
Bacterial colonization and the resultant inflammation of 
renal parenchyma were reflected by a significant decre-
ase in the number of medullary nephrons in animals 
from group 2 (inoculated with 107 cfu/ml of E. coli), as 
well as by the loss of both cortical and medullary neph-
rons in rats from group 3 (inoculated with 109 cfu/ml). 
These lesions were associated with impaired diuresis, an 
increase in CreaS level and a decrease in ClCr, a marker 
of GFR. At 14 and 21 days after induction of pyeloneph-
ritis, 24-h urine output in animals from group 2 (107 cfu/
ml) and 3 (109 cfu/ml) was ~ 50% and ~ 40% lower than at 
the baseline. Since reduced or sustained urine produc-
tion is a diagnostic criterion for AKI, it can be hypothe-
sized that rats exposed to intermediate or high dose of 
E. coli (107 cfu/ml or 109 cfu/ml, respectively) developed 
this condition between 7 and 21 days of the experiment 
(Figure 2, Table 2). 
Also an increase in CreaS by 40% at day 7 in group 3 (ani-
mals inoculated with 109 cfu/ml of E. coli) and by 35% 
at day 14 in group 2 (rats exposed to 107 cfu/ml of the 
bacteria) points to the deterioration of renal function. 
A similar 30-40% increase in serum creatinine between 
3 and 14 day of the experiment was reported by Maleki-
nejad et al. after the administration of 106-107 cfu/ml of 
E. coli to renal parenchyma [21]. Markedly more evident, 
a nearly five-fold increase in CreaS was documented by 
Sener et al., who induced interstitial pyelonephritis by 
injecting 1010 cfu/ml of E. coli [32]. In our experiment, 
the increase in CreaS was reflected by a decrease in GFR, 
by 48% at day 14 in animals from group 2 (inoculated 
with 107 cfu/ml) and by 43% and 52% at days 7 and 14, 
respectively, in rats from group 3, i.e. those exposed to 
E. coli at 107 cfu/ml. A substantially greater reduction of 
GFR, by even 71%, was previously reported by Heyman 
et al. in the model AKI induced by the administration 
of a contrast agent [11]. With no doubt, the degree of 
renal function impairment, expressed by an increase 
in serum creatinine and GFR reduction, depends on the 
route via which the triggering factor was administered 
(interstitial, transurethral), as well as on the type (bac-
teria, contrast agent) and dose of the latter. This is likely 
the reason why an increase in serum creatinine in rats 
inoculated with the intermediate dose of E. coli was obse-
rved later than in the group exposed to the larger ino-
culum. Since an increase in CreaS is another diagnostic 
criterion of AKI [29], our findings imply that transure-
thral administration of E. coli at 107 cfu/ml and 109 cfu/
ml induced AKI between 7 and 21 days post-inoculation, 
and functional impairment of the kidneys was propor-
tional to the inoculum size.
Electrolyte concentrations during the course of AKI 
are important laboratory parameters not only in view 
of potentially harmful consequences of dyselectroly-
temia, but also due to the fact that their changes may 
Body temperature
None of the examined animals presented with elevated 
body temperature at day 7, 14 and 21.
dIscussIon
Urine samples obtained at various stages of the expe-
riment were examined microbiologically in order to 
verify if transurethral inoculation with E. coli resulted 
in the development of UTI in all the studied groups. In 
humans, the diagnosis of UTI is confirmed isolating bac-
teria from routinely collected biological material, urine. 
The bacterial count in urine is verified against the strict 
diagnostic criteria of UTI [13,38]. Due to the lack of stan-
dardized methodology of urine collection for microbio-
logical purposes and specific diagnostic criteria for UTI 
in laboratory animals, we were only able to confirm the 
presence of bacteria in the urinary tract. The fact that 
no statistically significant differences in bacterial counts 
were found between animals inoculated with various 
doses of E. coli likely reflected the lack of standardized 
methodology for urine collection. Therefore, markers of 
renal damage were determined to confirm the activity 
and severity of urinary tract inflammation.
Histopathologic examination documented inflammatory 
lesions in renal parenchyma of all animals with experi-
mentally induced pyelonephritis. The chronic character 
of lesions observed at 21 days of UTI induction implies 
that an acute process took place at early stages of the 
experiment.
Further analysis, including diagnostic parameters of AKI 
recommended by KDIGO, i.e. diuresis and CreaS, demon-
strated that renal filtering function was substantially 
impaired solely in the groups inoculated with interme-
diate or high dose of E. coli (groups 2 and 3). At 7 and 
14 days post-inoculation, values of these parameters in 
the two groups differed significantly from those deter-
mined at the baseline, which implies that an acute phase 
of the kidney injury developed earlier than suggested by 
histopathologic findings. This hypothesis was further 
supported by the data on urinary concentration of IL-6 
(Table 5).
Urinary IL-6 is a marker of inflammatory activity within 
the urinary tract [4,25]. Moreover, it is used as an early 
marker of AKI and a prognostic factor for permanent 
renal damage [5,16,19]. Rugo et al. analyzed urinary 
excretion of IL-6 during the course of pyelonephritis. 
They observed that urinary concentrations of IL-6 were 
the highest at 6-12 h after activation of the inflamma-
tory process, and then decreased gradually down to 
their baseline level [30]. In the hereby presented expe-
riment, we did not measure urinary IL-6 at early stages 
of UTI. However, urinary levels of IL-6 after inoculation 
with both intermediate and high dose of E. coli (107 cfu/
ml and 109 cfu/ml for group 2 and 3, respectively), were 
the highest at day 14. This implies that both these gro-
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of E. coli may result either in the development of renal 
AKI or in systemic infection. This observation seems 
to be vital from a clinical perspective, suggesting that 
even a patient with asymptomatic bacteriuria, who does 
not qualify for antibacterial treatment in line with cur-
rent therapeutic guidelines, may develop tubulointer-
stitial nephritis and thus be at increased risk for acute 
or chronic renal damage. Consequently, all patients with 
asymptomatic bacteriuria should be optimally subjected 
to molecular analyses to identify genotypic profile of 
virulence factors expressed by their E. coli isolates, and 
antibiotic therapy should be implemented whenever 
a strain expressing fimbriae responsible for colonization 
of structures other than those present in urinary blad-
der (type II fimbriae – P, S involved in colonization of 
renal structures and vascular endothelium) was detec-
ted [20]. According to literature, 30-50% of patients with 
lower urinary tract infections may also present with 
asymptomatic pyelonephritis [6]. Thus, phenotyping 
seems to be the most reasonable diagnostic option, espe-
cially in individuals with other risk factors of acute kid-
ney injury, such as older age, diabetes mellitus, chronic 
kidney disease, sepsis and circulatory failure.
The data presented in this study imply that the experi-
mental model for AKI is dose-dependent. Irrespective of 
the inoculum size, administration of E. coli isolate being 
capable of colonizing upper urinary tract (i.e. expressing 
type II fimbriae) always led to UTI and resultant pyelo-
nephritis. However, the amount of inoculated bacteria 
determined the severity of the infection and the extent 
of inflammation in a dose-dependent manner. While 
transurethral inoculation with highly virulent E. coli at 
both 107 and 109 cfu/ml resulted in pyelonephritis, the 
lower dose induced solely an isolated AKI, whereas ino-
culation with the higher dose resulted not only with 
ascending pyelonephritis, but also with AKI of prerenal 
etiology, probably linked to bacteremia and urosepsis.
To the best of our knowledge, none of the previous stu-
dies analyzed the relationship between the size of E. coli 
inoculum used to induce pyelonephritis and biochemical 
indicators of renal function. As stated above, transureth-
ral administration of E. coli, regardless of the inoculum 
size, will always result in renal inflammation. Inocula-
tion with a higher dose of E. coli, 107 cfu/ml or 109 cfu/
ml, may pose a risk of AKI. According to literature, the 
later condition may develop within a few hours to seve-
ral days after the administration of a triggering factor 
[22,26]. Our findings presented in this study, specifically 
the changes in the markers of AKI (diuresis, CreaS), sug-
gest that the duration of the latency period correlates 
inversely with bacterial inoculum size. Future studies, 
involving microbiological cultures of the blood, deter-
mination of other markers of kidney damage and moni-
toring of renal function at shorter time intervals, should 
explain the role of systemic bacterial infection in AKI 
development, the timing of functional renal deteriora-
tion and the size of inoculum necessary to develop fully 
symptomatic kidney damage.
be specific for the cause of kidney damage [33]. FENa is 
an example of a parameter used in the differential dia-
gnosis of various AKI forms [10]. According to literature, 
a decrease in FENa is specific for the prerenal etiology 
of this condition, whereas an increase in this parameter 
points to renal abnormalities as a cause of AKI [8,16]. Our 
findings suggest that in rats from group 3, AKI not only 
resulted from renal damage but had also a prerenal com-
ponent, probably as a consequence of systemic bacte-
rial infection. The decrease in FENa observed in animals 
from group 3 (109 cfu/ml) was not associated with hypo-
volemia resulting from fever or reduced water intake. 
Consequently, the prerenal etiology of AKI was probably 
related to the dilation of the vascular bed by bacterial 
toxins and other systemic effects of vasodilating agents 
released during the course of infection.
Rats exposed to the highest dose of E. coli (109 cfu/ml) 
showed a decrease in FENa at each stage of the experi-
ment, by 63%, 32% and 53% at days 7, 14 and 21, respec-
tively. An opposite phenomenon was observed in the 
group exposed to the intermediate dose of the bacte-
ria (10 cfu/ml), in which FENa at day 14 corresponded 
to 147% of the baseline value. These findings point to 
a renal etiology of AKI in group 2 (107cfu/ml) and a pre-
renal etiology of this condition in group 3 (109cfu/ml). 
Langenberg et al. analyzed a model AKI induced by the 
administration of E. coli (3.9 x 109 cfu/ml) to the blood-
stream, and observed a 92% reduction of FENa [17]. Pro-
bably, this relatively greater decrease in FENa reflected 
not only the different route of administering bacterial 
inoculum and resultant greater systemic E. coli count 
than in our study, but also the absence of a renal compo-
nent of AKI. Another argument for the prerenal origin of 
kidney injuries in rats from group 3 (109 cfu/ml) seems 
to be a decrease in FEUrea, another marker of AKI etio-
logy [15]. Animals inoculated with the highest dose of E. 
coli were the only group presenting with lower FEUrea 
values, as compared to both the baseline and to other 
rats. However, none of these differences were statisti-
cally significant, which implies that this parameter is 
of secondary importance and more attention should be 
paid to FENa. In this study, we did not compare empiri-
cal FENa and FEUrea values to any reference or cutoff 
limits, but analyzed their relative changes from the 
baseline. A relative decrease in both parameters obse-
rved in group 3 (109 cfu/ml) points to a likely prerenal 
etiology of the kidney injury in animals exposed to the 
highest dose of E. coli (Tables 3 and 4).
We found an association between the size of E. coli ino-
culum and the effects of its administration. Inoculation 
with the lowest dose of E. coli (105 cfu/ml) resulted in 
the least pronounced impairment of renal function, but 
even in this group histopathologic examination reveal 
bacterial colonization of kidney parenchyma. The larger 
the size of E. coli inoculum, the more evident the altera-
tions of analyzed parameters and the greater the degree 
of renal inflammation. Our findings imply that, depen-
ding on the inoculum size, transurethral administration 
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